

Mitchell E Horwitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2329165/publications.pdf>

Version: 2024-02-01

93
papers

2,848
citations

236925

25
h-index

175258

52
g-index

93
all docs

93
docs citations

93
times ranked

3466
citing authors

#	ARTICLE	IF	CITATIONS
1	Home-Based Hematopoietic Cell Transplantation in the United States. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 207.e1-207.e8.	1.2	3
2	The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis. <i>Journal of Personalized Medicine</i> , 2022, 12, 571.	2.5	0
3	Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 137-143.	2.4	15
4	Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 181.e1-181.e9.	1.2	18
5	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. <i>Blood</i> , 2021, 137, 420-428.	1.4	119
6	Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 262.e1-262.e11.	1.2	7
7	Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant. <i>Blood Cancer Journal</i> , 2021, 11, 92.	6.2	2
8	A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. <i>PLoS ONE</i> , 2021, 16, e0252995.	2.5	3
9	Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. <i>Blood</i> , 2021, 138, 1429-1440.	1.4	54
10	Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2826-2833.	2.4	5
11	Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 540-544.	1.2	11
12	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma—type Richter syndrome. <i>Blood Advances</i> , 2021, 5, 3528-3539.	5.2	24
13	Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 784.e1-784.e7.	1.2	4
14	Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	2
15	Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-up from a Single Center. <i>Blood</i> , 2021, 138, 1827-1827.	1.4	1
16	Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 568-580.	2.0	8
17	Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. <i>PLoS ONE</i> , 2020, 15, e0238824.	2.5	4
18	Clinical and Neuroimaging Correlates of Post-Transplant Delirium. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2323-2328.	2.0	0

#	ARTICLE	IF	CITATIONS
19	Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1597-1606.	2.0	7
20	Guidelines for Cord Blood Unit Thaw and Infusion. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1780-1783.	2.0	5
21	Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2020, 136, 18-19.	1.4	0
22	Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells. <i>International Journal of Hematology</i> , 2019, 110, 50-58.	1.6	19
23	Intestinal Acute Graft-versus-Host Disease: A Bug Highway to the Bloodstream. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e250-e251.	2.0	0
24	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. <i>Journal of Clinical Oncology</i> , 2019, 37, 367-374.	1.6	110
25	Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. <i>JAMA Dermatology</i> , 2019, 155, 833.	4.1	6
26	Rapid and Robust CD4+ and CD8+ T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S55.	2.0	2
27	Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. <i>Blood Advances</i> , 2019, 3, 875-883.	5.2	25
28	Small-molecule nicotinamide for ex vivo expansion of umbilical cord blood. <i>Experimental Hematology</i> , 2019, 80, 11-15.	0.4	18
29	Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality. <i>Blood</i> , 2019, 134, 5731-5731.	1.4	0
30	Shared Decision-Making in Hematopoietic Stem Cell Transplantation for Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 883-884.	2.0	9
31	Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1187-1195.	2.0	38
32	Stem Cell Transplantation and Informatics: Current Considerations. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 659-665.	2.0	5
33	HSCT-GAVE as a Manifestation of Chronic Graft versus Host Disease: A Case Report and Review of the Existing Literature. <i>Case Reports in Transplantation</i> , 2018, 2018, 1-5.	0.3	1
34	Use of a Processed Hematopoietic Stem Cell Product (FCRx) in Unmatched Related and Unrelated Donor Recipient Pairs Is Associated with High Levels of Donor Chimerism and Donor-Specific Tolerance to Kidney Allografts. <i>Blood</i> , 2018, 132, 202-202.	1.4	0
35	Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation. <i>Blood</i> , 2018, 132, 2123-2123.	1.4	0
36	Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function. <i>Blood</i> , 2018, 132, 4594-4594.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. <i>Hematological Oncology</i> , 2017, 35, 752-759.	1.7	5
38	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2017, 35, 1154-1161.	1.6	495
39	Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 882-896.	2.0	117
40	Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1151-1157.	2.0	32
41	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. <i>Blood</i> , 2017, 130, 2131-2145.	1.4	37
42	Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1949-1954.	2.0	4
43	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4011.	1.6	258
44	Increased TLR7 Signaling of BCR-Activated B Cells in Chronic Graft-Versus Host Disease (cGVHD). <i>Blood</i> , 2017, 130, 75-75.	1.4	0
45	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/II Trial. <i>Blood</i> , 2017, 130, 847-847.	1.4	8
46	Reply to Strahilevitz and Shapira. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw813.	5.8	0
47	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1197-1205.	2.0	17
48	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. <i>Journal of Hematology and Oncology</i> , 2016, 9, 71.	17.0	20
49	Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity. <i>Advances in Radiation Oncology</i> , 2016, 1, 272-280.	1.2	10
50	Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 999-1006.	5.8	63
51	Ex Vivo Expansion or Manipulation of Stem Cells to Improve Outcome of Umbilical Cord Blood Transplantation. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 12-18.	2.3	14
52	NiCord single unit expanded umbilical cord blood transplantation: Results of phase I/II trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7004-7004.	1.6	3
53	Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation. <i>Cytotherapy</i> , 2015, 17, 730-738.	0.7	30
54	Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. <i>British Journal of Haematology</i> , 2015, 168, 405-412.	2.5	39

#	ARTICLE	IF	CITATIONS
55	Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. <i>Blood</i> , 2015, 126, LBA-8-LBA-8.	1.4	59
56	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 257-263.	2.0	15
57	Increased BCR responsiveness in B cells from patients with chronic GVHD. <i>Blood</i> , 2014, 123, 2108-2115.	1.4	86
58	Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. <i>Journal of Clinical Investigation</i> , 2014, 124, 3121-3128.	8.2	224
59	Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America. <i>Blood</i> , 2013, 122, 768-768.	1.4	0
60	Immune Recovery in Adult Patients after Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1664-1676.e1.	2.0	94
61	Surgical Mask Usage Reduces the Incidence of Parainfluenza Virus 3 in Recipients of Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 462-462.	1.4	3
62	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	32
63	Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. <i>Current Opinion in Oncology</i> , 2011, 23, 197-202.	2.4	39
64	Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011, 118, 4127-4127.	1.4	9
65	Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels. <i>Blood</i> , 2011, 118, 3009-3009.	1.4	0
66	The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,. <i>Blood</i> , 2011, 118, 4065-4065.	1.4	0
67	Differences in Stem Cell Collection Practices and Related Outcomes Between Centers That Conduct and Do Not Conduct Aphaeresis on Weekends. <i>Blood</i> , 2011, 118, 1925-1925.	1.4	0
68	Non-myeloablative umbilical cord blood transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 231-236.	1.7	3
69	Long-Term Follow-up of Adults with Severe Sickle Cell Disease After Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning. <i>Blood</i> , 2010, 116, 261-261.	1.4	3
70	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. <i>Blood</i> , 2010, 116, 3523-3523.	1.4	0
71	Efficacy and Safety of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil®) + G-CSF In Adult Patients with Non-Hematologic Malignancies. <i>Blood</i> , 2010, 116, 2249-2249.	1.4	0
72	Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies. <i>Blood</i> , 2010, 116, 3541-3541.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Donor Cell Leukemia: A Clinicopathological Study of 9 Cases and a Comprehensive Review of Literature.. Blood, 2010, 116, 3466-3466.	1.4	0
74	A Comprehensive Comparison Immune Recovery In Adult Patients Following Allogeneic Umbilical Cord Blood, Matched Sibling and Matched Unrelated Donor Stem Cell Transplantation. Blood, 2010, 116, 2313-2313.	1.4	0
75	Long-Term Survival and Late Deaths After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism.. Blood, 2009, 114, 3320-3320.	1.4	0
76	Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients. Biology of Blood and Marrow Transplantation, 2008, 14, 591-594.	2.0	54
77	Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood, 2008, 112, 342-342.	1.4	1
78	Total Body Irradiation 1350cGy/Fludarabine (TBI/FLU) vs Myeloablative Busulfan/Fludarabine (Bu/Flu) Preparation in Adult Recipients of Dual Umbilical Cord Blood (UCB) Transplantation: Superior Engraftment with Low Treatment-Related Mortality. Blood, 2008, 112, 4403-4403.	1.4	0
79	Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.. Blood, 2008, 112, 3325-3325.	1.4	0
80	Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution. Journal of Clinical Oncology, 2007, 25, 690-697.	1.6	188
81	Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics. Biology of Blood and Marrow Transplantation, 2007, 13, 1422-1426.	2.0	47
82	Sources of Human and Murine Hematopoietic Stem Cells. Current Protocols in Immunology, 2007, 79, Unit 22A.2.	3.6	3
83	Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients.. Blood, 2007, 110, 2007-2007.	1.4	1
84	Chronic graft-versus-host disease. Blood Reviews, 2006, 20, 15-27.	5.7	123
85	Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.. Blood, 2006, 108, 5399-5399.	1.4	1
86	A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.. Blood, 2005, 106, 5181-5181.	1.4	1
87	Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.. Blood, 2005, 106, 2896-2896.	1.4	5
88	Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.. Blood, 2005, 106, 5501-5501.	1.4	0
89	Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.. Blood, 2005, 106, 4623-4623.	1.4	0
90	Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. Biology of Blood and Marrow Transplantation, 2004, 10, 569-575.	2.0	51

#	ARTICLE	IF	CITATIONS
91	Hematopoietic stem cell transplantation for complete IFN- $\hat{1}^3$ receptor 1 deficiency: A multi-institutional survey. <i>Journal of Pediatrics</i> , 2004, 145, 806-812.	1.8	92
92	Campath-1H May Have Activity in the Treatment of Multiple Myeloma.. <i>Blood</i> , 2004, 104, 4931-4931.	1.4	1
93	Persistent <i>Mycobacterium avium</i> infection following nonmyeloablative allogeneic peripheral blood stem cell transplantation for interferon- $\hat{1}^3$ receptor-1 deficiency. <i>Blood</i> , 2003, 102, 2692-2694.	1.4	36